生物制剂可延缓儿童克罗恩病进展,但未能减少早期手术
基于儿童炎症性肠病协作研究组登记库1442例≤16岁克罗恩病患儿(2002年1月至2014年12月诊断),10年首次肠手术风险为26%,5年手术风险2002至2014年间未变、维持在13%至14%。早期使用生物制剂(诊断后<3个月)与延缓进展至狭窄或穿透性疾病(但不包括手术)相关,该效应在病程5年后才显现(风险比0.85,95%CI 0.76-0.95)。
要点
- 10年首次肠手术风险为26%,多数手术发生在诊断后3年内。
- 5年手术风险2002至2014年间未变,维持在13%至14%。
- 早期使用生物制剂与延缓进展至狭窄或穿透性疾病相关,但未能减少早期手术。
核心结论
- 在就诊时或就诊后不久即有明显且进展性疾病的患儿中,即使早期使用生物制剂,早期手术也难以避免。
- 早期使用生物制剂(诊断后<3个月)可延缓后期进展至狭窄和(或)穿透性疾病,但该效应可能在初始管理决策数年之后才显现。
研究设计与样本
- 研究为儿童炎症性肠病协作研究组登记库的起始队列分析,纳入2002年1月至2014年12月诊断的1442例≤16岁克罗恩病患儿。
- 数据在诊断时、诊断后30天、之后每季度及住院期间收集,随访最长12年。
- 主要目标为确定儿童克罗恩病10年手术风险,次要目标为确定早期使用生物制剂(诊断后<3个月)是否影响疾病进展风险。
主要发现
- 10年首次肠手术风险为26%。
- 5年肠手术风险2002至2014年间未变化,维持在13%至14%。
- 大多数手术发生在诊断后3年内。
- 手术的唯一预测因素为诊断时的疾病行为;与狭窄型、穿透型或两者兼有相比,炎症型克罗恩病手术风险最低。
- 早期使用生物制剂与延缓进展至狭窄或穿透性疾病(但不包括手术)相关,该效应仅在病程5年后才显现(风险比0.85,95%CI 0.76-0.95)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Up to 30% of patients with Crohn's disease (CD) require surgery within the first 5 years from diagnosis. We investigated the recent risk of bowel surgery in an inception cohort of pediatric patients with CD and whether early use of biologics (tumor necrosis factor antagonists) alters later disease course. METHODS: We collected data from the Pediatric Inflammatory Bowel Disease Collaborative Research Group registry on 1442 children (age, ≤16 y) diagnosed with CD from January 2002 through December 2014. Data were collected at diagnosis, 30 days following diagnosis, and then quarterly and during hospitalizations for up to 12 years. Our primary aim was to determine the 10-year risk for surgery in children with CD. Our secondary aim was to determine whether early use of biologics (<3 mo of diagnosis) affected risk of disease progression. RESULTS: The 10-year risk of first bowel surgery was 26%. The 5-year risk of bowel surgery did not change from 2002 through 2014, and remained between 13% and 14%. Most surgeries occurred within 3 years from diagnosis. The only predictor of surgery was disease behavior at diagnosis. CD with inflammatory behavior had the lowest risk of surgery compared to stricturing disease, penetrating disease, or both. We associated slowing of disease progression to stricturing or penetrating disease (but not surgery) with early use of biologics, but this effect only became evident after 5 years of disease. Our results indicate that biologics slow disease progression over time (hazard ratio, 0.85; 95% CI, 0.76-0.95). CONCLUSIONS: In an analysis of data from a registry of pediatric patients with CD, we found that among those with significant and progressing disease at or shortly after presentation, early surgery is difficult to prevent, even with early use of biologics. Early use of biologics (<3 mo of diagnosis) can delay later disease progression to stricturing and/or penetrating disease, but this affect could become evident only years after initial management decisions are made.
引用
- Kerur B, Machan JT, Shapiro JM, et al. Biologics Delay Progression of Crohn's Disease, but Not Early Surgery, in Children. Clin Gastroenterol Hepatol. 2018. PMID: 29486253. doi:10.1016/j.cgh.2018.02.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。